Brady Collins
The blood-brain barrier (BBB) is a protective mechanism that prevents harmful substances in the blood from entering the brain. It is not fully developed in infants until at least six weeks after birth, leaving newborns vulnerable to toxins and infections. There is some concern that vaccines, such as the Hepatitis B vaccine, may contain substances that can cross the BBB and potentially cause adverse effects, especially in infants. However, the role of vaccines in compromising the BBB is still under active investigation, with some studies suggesting that vaccines can induce neuroinflammation and increase the BBB's permeability. Scientists are also exploring ways to utilize this mechanism to deliver drugs to the brain for treating neurological diseases.
| Characteristics | Values |
|---|---|
| Vaccines that can cause neuroinflammation | Hepatitis B vaccine, MMR vaccine |
| Components that can cause neuroinflammation | Hepatitis B antigen, aluminum adjuvant, IL-4 |
| Conditions caused by neuroinflammation | ASD, schizophrenia, ADHD, mood disorders, multiple sclerosis |
| Substances that can weaken the blood-brain barrier | Ultrasound, sodium deoxycholate |
| Substances that can pass through the blood-brain barrier | Lipid nanoparticles, CCL2/MCP-1 |
Explore related products
What You'll Learn
Hepatitis B vaccine and neurobehavioural impairments
The Hepatitis B vaccine (HBV) is administered to over 70% of neonates worldwide. However, it is not known whether this neonatal vaccination affects brain development.
A 2016 study found that neonatal hepatitis B vaccination impaired the behaviour and neurogenesis of mice in early adulthood. The study observed that the vaccination induced an anti-inflammatory cytokine response lasting 4-5 weeks, indicated by elevated IL-4 levels. Three weeks after the vaccination, HBV-mice showed delayed hippocampal neuroinflammation. The study concluded that neonatal over-exposure to systemic IL-4 may influence brain and behaviour, leading to neurobehavioural impairments.
Another study found that CD8-positive T-cells decreased neurogenesis and induced anxiety-like behaviour following hepatitis B vaccination.
Further research has shown that IL-4 mediates the delayed neurobehavioural impairments induced by neonatal hepatitis B vaccination, involving the permeability of the neonatal blood-brain barrier and the down-regulation of the IL-4 receptor. This suggests that clinical events concerning neonatal IL-4 over-exposure, including neonatal hepatitis B vaccination, may adversely affect brain development and cognition.
While these studies indicate a potential link between the Hepatitis B vaccine and neurobehavioural impairments, it is important to note that the exact mechanism of these effects is not yet fully understood. More research is needed to confirm and further elucidate these findings.
Relieving Post-Vaccination Pain in Babies: What You Can Do
You may want to see also
Explore related products
Flu vaccines and seizures
The blood-brain barrier (BBB) is not intact in infants until at least six weeks of life. This is why newborns with a fever are subjected to a spinal tap to rule out meningitis. Any virus or bacteria that a newborn is exposed to can go directly to the nervous system.
There is a small increased risk of febrile seizures in certain age groups after some vaccines. Fevers can cause a child to experience spasms or jerky movements called seizures. Seizures caused by fever are called "febrile seizures". They are most common with fevers of 102°F (38.9°C) or higher, but they can also happen at lower body temperatures or when a fever is going down. Most febrile seizures last for less than one or two minutes and nearly all children who have a febrile seizure recover quickly. Febrile seizures do not cause any permanent harm and do not have any lasting effects.
Fevers can be caused by common childhood illnesses like colds, the flu, an ear infection, or roseola. Vaccines can sometimes cause fevers, but febrile seizures are uncommon after vaccination. The risk of febrile seizures is increased when the influenza and pneumococcal conjugate vaccines are given simultaneously, to an estimated rate of 17.5 per 100,000 doses. The flu shot was not associated with an increased risk of febrile seizures when it was given on a different day from the pneumococcal vaccine. Studies have not shown an increased risk for febrile seizures after the DTaP vaccine, except when it is given at the same time as the flu shot.
There have been several studies on the relationship between flu vaccines and febrile convulsions. A study on the risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix) found that there were 38 cases of seizures with a fatal outcome in patients known to have epilepsy. However, no conclusion about a causal relation could be drawn. Another study found that there was no increased risk of febrile seizures after the first dose of the seasonal flu vaccine, which is rare in children and the healthy population.
It is important to note that vaccines are intended to "educate" the immune system, and each new vaccine to which individuals are exposed “will potentially alter the dynamics of their immune system”. While there may be a small risk of vaccine-induced febrile seizures, the benefits of vaccination greatly outweigh the minimal risk of vaccine complications.
Neck Lumps: MMR Vaccine Side Effect?
You may want to see also
Explore related products
ASD and other neurodevelopmental disorders
The blood-brain barrier is not intact in infants until at least six weeks after birth. This is why newborns with a fever are subjected to a spinal tap to rule out meningitis, as their nervous system is vulnerable to any bacteria or virus they are exposed to.
Some sources claim that the Hepatitis B vaccine, which contained Thimerosal (resulting in mercury crossing into the brain) between 1991 and 1999, was dangerous for newborns because of the immature blood-brain barrier. A nurse, Mary Barbera, claims that this could be a reason for the surge of autism in the '90s. However, other sources refute this claim, stating that there is no link between the MMR vaccine and autism.
A 2018 study by Chinese researchers found that the hepatitis B vaccine induced neuroinflammation in neonatal mice, increasing the blood-brain barrier's permeability. Another study by Andrew Wakefield in 1998 hypothesised that the MMR vaccine caused intestinal inflammation, leading to harmful proteins entering the bloodstream and causing autism. However, this paper was deemed flawed due to the high prevalence of autism diagnoses in England in 1998, which would naturally result in a high number of recently administered MMR vaccines. Further studies in Japan, the UK, Finland, Denmark, and the US have failed to find a causal link between the MMR vaccine and autism.
Maternal immune activation has been a focus of research, with studies showing that immune challenges and alterations in inflammatory cytokines can impact fetal brain development and increase the risk of ASD, schizophrenia, and other neurodevelopmental disorders. Additionally, imbalances in gut microbes can alter the distribution of neurotoxins, affecting the integrity of the blood-brain barrier and potentially leading to neurodevelopmental issues.
RSV Vaccine: How Often to Get the Shot?
You may want to see also
Explore related products
Maternal immune activation and fetal neurodevelopment
The maternal immune system has been recognised as a critical participant in the processes that propel embryonic and fetal development. Fetal neurodevelopment in utero is shaped by both systemic maternal immunity and local processes at the maternal–fetal interface. Maternal immune activation (MIA) has been implicated in a broad range of distinct disorders in offspring, including autism spectrum disorder (ASD), microcephaly, schizophrenia, and epilepsy.
MIA is often used as a solitary manipulation in animal models to examine how perturbations of the developing immune system may contribute to specific symptoms of neurodevelopmental disorders (NDDs). Rodent models of MIA have been useful in elucidating neural mechanisms that may become disrupted by MIA. For example, rodent models have shown that exposure to early-life immune activation can affect the number and function of microglia, disrupt synaptic maturation and pruning, and result in neural circuit remodelling and deficits in neural function and behaviour.
In humans, epidemiological evidence suggests that the risk of being diagnosed with an NDD increases significantly if the mother had a viral or bacterial infection during the first or second trimester of pregnancy. Maternal infections have been identified as a major risk factor for neurodevelopmental disorders in offspring. The maternal immune response to infection can vary depending on the type of infectious agent and whether a robust febrile response occurs. Medications that attenuate febrile response or cytokine production may lessen the risk of NDDs associated with prenatal infection.
MIA in the absence of a pathogen is sufficient to elicit brain maldevelopment and behavioural abnormalities in offspring, indicating that the maternal response to infection, rather than the infection itself, may be the primary driver of neurodevelopmental disorders. Studies in rats have shown that maternal PolyI:C exposure during early gestation results in a robust increase in expression of genes related to antiviral inflammation and a corresponding decrease in transcripts.
Vaccines: Autoimmune Families Face a Tough Choice
You may want to see also
Explore related products
Lipid nanoparticles and brain-targeted treatments
The blood-brain barrier (BBB) is a protective layer of cells that prevents foreign or potentially harmful agents from entering the brain. This barrier poses a challenge to the development of neurological treatments as it obstructs the delivery of drugs to the brain. However, recent advancements in nanotechnology have led to the development of lipid nanoparticles (LNPs) that can cross the BBB and target specific cells within the brain, opening up possibilities for next-generation neurological treatments.
Lipid nanoparticles are vessels containing therapeutic material such as mRNA, acting as delivery vehicles. Researchers at the University of Pennsylvania School of Engineering and Applied Science have successfully modified LNPs to cross the BBB by attaching peptides that target specific receptors on endothelial cells and neurons. This modification enhances mRNA transfection in brain cells and has shown promising results in mouse models.
One advantage of LNPs is their ability to deliver mRNA to the brain, which has been crucial in the development of COVID-19 mRNA vaccines. Additionally, LNPs can be designed to facilitate their movement across the BBB, even without specific cell targeting capabilities. This non-specific approach was previously demonstrated by the same research group working on Alzheimer's disease pathology.
Lipid nanovesicles, a type of lipid nanoparticle, have shown potential in the targeted treatment of spinal cord injuries. They have higher biocompatibility and circulating stability, and they can penetrate the blood-spinal cord barrier (BSCB) to target specific cells. The size and charge of nanoparticles are important considerations in targeted therapy. Nanoparticles with a diameter of approximately 50 nm are more easily internalized, and negatively charged nanoparticles are preferred to avoid disrupting the BSCB.
Nose-to-brain targeted nanoparticles delivery is another promising approach that bypasses the BBB completely. This method involves administering drugs through the nasal cavity, allowing them to enter the brain through olfactory and trigeminal nerve pathways. Nanostructured lipid carriers (NLCs) are a type of lipid nanoparticle that combines solid and liquid lipids, offering higher encapsulation efficiency and stability while maintaining low toxicity. Overall, lipid nanoparticles have the potential to revolutionize brain-targeted treatments by safely and efficiently delivering drugs to specific regions of the brain.
Vaccines Grown on Aborted Cells: Ethical or Not?
You may want to see also
Frequently asked questions
It is generally understood that the blood-brain barrier (BBB) protects the brain from foreign substances like vaccines. However, some studies have shown that certain components of vaccines, such as aluminum adjuvant nanoparticles, can cross the BBB and cause neuroinflammation and brain damage.
The blood-brain barrier can be compromised by immune dysregulation, allowing substances like vaccines to pass through. In addition, lipid nanoparticles in vaccines can carry substances like antibodies and messenger RNA (mRNA) through the BBB.
The passage of vaccines through the BBB has been hypothesized to contribute to neurodevelopmental disorders like ASD (autism) and schizophrenia. It may also cause neurobehavioral impairments and increase the risk of conditions like attention deficit hyperactivity disorder (ADHD) and mood disorders.
Yes, the ability of vaccines to cross the BBB may have therapeutic potential for treating neurological diseases. mRNA therapies, for example, could be used to replace missing proteins or edit faulty genes in the brain.
